XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

Summary

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.

Timeline

Start

2026-08

Primary completion

2029-11

Completion

2029-11

Drugs

Indications